Myriad Genetics Fourth Quarter 2025 Financial Earnings

02/23/2026 | 1:30 pm PST / 4:30pm EST

Webcast Link
View Presentation

Events & Presentations

View all events

Financial Reports and Filings

Date Filing Title Downloads
02/24/2026 S-3 Simplified registration form RTF XLS PDF HTML XBRL
02/24/2026 10-K Annual report which provides a comprehensive overview of the company for the past year RTF XLS PDF HTML XBRL
02/23/2026 8-K Report of unscheduled material events or corporate event RTF XLS PDF HTML XBRL
02/11/2026 SCHEDULE 13G/A SCHEDULE 13G/A - Description RTF XLS PDF HTML XBRL
02/09/2026 SCHEDULE 13G SCHEDULE 13G - Description RTF XLS PDF HTML XBRL
02/03/2026 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
02/03/2026 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
02/03/2026 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
02/03/2026 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
01/13/2026 SCHEDULE 13G SCHEDULE 13G - Description RTF XLS PDF HTML XBRL
View all filings

Latest News

Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact of Myriad’s Precise MRD, Prolaris, and MyRisk tests Thumbnail

Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact of Myriad’s Precise MRD, Prolaris, and MyRisk tests

Feb 24, 2026 | Products

Read more
Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance Reflecting Strengthened Execution Thumbnail

Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance Reflecting Strengthened Execution

Feb 23, 2026 | Corporate | Financial

Read more
FirstGene Study Demonstrates High Analytical Sensitivity and Specificity for Each Component of the Test Thumbnail

FirstGene Study Demonstrates High Analytical Sensitivity and Specificity for Each Component of the Test

Feb 19, 2026 | Products

Read more
View all news releases

Quality, Innovation and Corporate Responsibility Report

Myriad Genetics has a strong commitment to operational excellence, innovation and being a good corporate partner. Our dedication to these important issues serve as the foundation to achieving our mission of advancing health and well-being for all.

Learn more about the actions we’re taking in quality, innovation, and corporate responsibility.

Read our QICR report

Quality, Innovation and Corporate Responsibility Report

Myriad Genetics has a strong commitment to operational excellence, innovation and being a good corporate partner. Our dedication to these important issues serve as the foundation to achieving our mission of advancing health and well-being for all.

Learn more about the actions we’re taking in quality, innovation, and corporate responsibility.

Read our QICR report